Belgija - anglų - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

bausch + lomb ireland - povidone iodinated 50 mg/ml - eye drops, solution - 50 mg/ml - povidone-iodine 50 mg/ml - povidone-iodine

Kenija - anglų - Pharmacy and Poisons Board

sphinx pharmaceuticals ltd 69512-00400 - povidone iodine - cutaneous liquid - povidone iodine10% solution - other ophthalmological anti-infectives

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

rx pharma-pack, inc. - bupivacaine hydrochloride (unii: 7tqo7w3vt8) (bupivacaine - unii:y8335394ro) - bupivacaine hydrochloride anhydrous 5 mg in 1 ml - marcaine is indicated for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures. only the 0.25% and 0.5% concentrations are indicated for obstetrical anesthesia. (see warnings .) experience with nonobstetrical surgical procedures in pregnant patients is not sufficient to recommend use of 0.75% concentration of marcaine in these patients. marcaine is not recommended for intravenous regional anesthesia (bier block). see warnings . the routes of administration and indicated marcaine concentrations are: - local infiltration - peripheral nerve block - retrobulbar block - sympathetic block - lumbar epidural 0.25%, 0.5%, and 0.75% (0.75% not for obstetrical anesthesia) - caudal - epidural test dose - dental blocks (see dosage and administration for additional information). standard textbooks should be consulted to determine the accepted procedures and techniques for the administration of marc

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

rx pharma-pack, inc. - bupivacaine hydrochloride (unii: 7tqo7w3vt8) (bupivacaine - unii:y8335394ro) - bupivacaine hydrochloride anhydrous 5 mg in 1 ml - marcaine is indicated for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures. only the 0.25% and 0.5% concentrations are indicated for obstetrical anesthesia. (see warnings .) experience with nonobstetrical surgical procedures in pregnant patients is not sufficient to recommend use of 0.75% concentration of marcaine in these patients. marcaine is not recommended for intravenous regional anesthesia (bier block). see warnings . the routes of administration and indicated marcaine concentrations are: - local infiltration - peripheral nerve block - retrobulbar block - sympathetic block - lumbar epidural  0.25%, 0.5%, and 0.75% (0.75% not for obstetrical anesthesia) - caudal - epidural test dose - dental blocks (see dosage and administration for additional information). standard textbooks should be consulted to determine the accepted procedures and techniques for the administration of mar

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

rx pharma-pack, inc. - bupivacaine hydrochloride (unii: 7tqo7w3vt8) (bupivacaine - unii:y8335394ro) - bupivacaine hydrochloride anhydrous 5 mg in 1 ml - marcaine is indicated for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures. only the 0.25% and 0.5% concentrations are indicated for obstetrical anesthesia. (see warnings .) experience with nonobstetrical surgical procedures in pregnant patients is not sufficient to recommend use of 0.75% concentration of marcaine in these patients. marcaine is not recommended for intravenous regional anesthesia (bier block). see warnings . the routes of administration and indicated marcaine concentrations are: - local infiltration - peripheral nerve block - retobulbar block - sympathetic block - lumbar epidural  0.25%, 0.5%, and 0.75%  (0.75% not for obstetrical anesthesia) - caudal - epidural test dose - dental blocks (see dosage and administration for additional information). standard textbooks should be consulted to determine the accepted procedures and techniques for the administration of ma

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

sa3, llc - lidocaine hydrochloride (unii: v13007z41a) (lidocaine - unii:98pi200987) - lidocaine hydrochloride anhydrous 20 mg in 1 ml - lidocaine hydrochloride injection, usp is indicated for production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks, when the accepted procedures for these techniques as described in standard textbooks are observed. lidocaine is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type. intramuscular where oral therapy is not feasible, injectable corticosteroid therapy, including kenalog-40 injection (triamcinolone acetonide injectable suspension, usp) is indicated for intramuscular use as follows:       allergic states : control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or season

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

ncs healthcare of ky, inc dba vangard labs - amiodarone hydrochloride (unii: 976728sy6z) (amiodarone - unii:n3rq532iut) - amiodarone hydrochloride 200 mg - because of its life-threatening side effects and the substantial management difficulties associated with its use (see warnings   below), amiodarone hydrochloride tablets are indicated only for the treatment of the following documented, life-threatening recurrent ventricular arrhythmias when these have not responded to documented adequate doses of other available antiarrhythmics or when alternative agents could not be tolerated. 1. recurrent ventricular fibrillation. 2. recurrent hemodynamically unstable ventricular tachycardia. as is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of amiodarone hydrochloride tablets favorably affects survival. amiodarone hydrochloride tablets should be used only by physicians familiar with and with access to (directly or through referral) the use of all available modalities for treating recurrent life-threatening ventricular arrhythmias, and who have access to appropriate monitoring facilities, including in-hospital and ambul

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

taro pharmaceuticals u.s.a., inc. - amiodarone hydrochloride (unii: 976728sy6z) (amiodarone - unii:n3rq532iut) - amiodarone hydrochloride 100 mg - amiodarone hydrochloride tablets are indicated for the treatment of documented, life-threatening recurrent ventricular fibrillation and life-threatening recurrent hemodynamically unstable tachycardia in adults who have not responded to adequate doses of other available antiarrhythmics or when alternative agents cannot be tolerated. - cardiogenic shock. - sick sinus syndrome, second- or third-degree atrioventricular block, bradycardia leading to syncope without a functioning pacemaker. - known hypersensitivity to the drug or to any of its components, including iodine. risk summary available data from postmarketing reports and published case series indicate that amiodarone use in pregnant women may increase the risk for fetal adverse effects including neonatal hypo- and hyperthyroidism, neonatal bradycardia, neurodevelopmental abnormalities, preterm birth and fetal growth restriction. amiodarone and its metabolite, desethylamiodarone (dea), cross the placenta. untreated underlying arrhythmias, including ventric

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

aurobindo pharma limited - amiodarone hydrochloride (unii: 976728sy6z) (amiodarone - unii:n3rq532iut) - amiodarone hydrochloride 200 mg - amiodarone hydrochloride tablets are indicated for the treatment of documented, life-threatening recurrent ventricular fibrillation and life-threatening recurrent hemodynamically unstable tachycardia in adults who have not responded to adequate doses of other available antiarrhythmics or when alternative agents cannot be tolerated. - cardiogenic shock. - sick sinus syndrome, second- or third-degree atrioventricular block, bradycardia leading to syncope without a functioning pacemaker. - known hypersensitivity to the drug or to any of its components, including iodine. risk summary available data from postmarketing reports and published case series indicate that amiodarone use in pregnant women may increase the risk for fetal adverse effects including neonatal hypo- and hyperthyroidism, neonatal bradycardia, neurodevelopmental abnormalities, preterm birth and fetal growth restriction. amiodarone and its metabolite, desethylamiodarone (dea), cross the placenta. untreated underlying arrhythmias, including ventric

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

major pharmaceuticals - amiodarone hydrochloride (unii: 976728sy6z) (amiodarone - unii:n3rq532iut) - amiodarone hydrochloride 200 mg - amiodarone hydrochloride tablets are indicated for the treatment of documented, life-threatening recurrent ventricular fibrillation and life-threatening recurrent hemodynamically unstable tachycardia in adults who have not responded to adequate doses of other available antiarrhythmics or when alternative agents cannot be tolerated. risk summary available data from postmarketing reports and published case series indicate that amiodarone use in pregnant women may increase the risk for fetal adverse effects including neonatal hypo- and hyperthyroidism, neonatal bradycardia, neurodevelopmental abnormalities, preterm birth and fetal growth restriction. amiodarone and its metabolite, desethylamiodarone (dea), cross the placenta. untreated underlying arrhythmias, including ventricular arrhythmias, during pregnancy pose a risk to the mother and fetus (see clinical considerations). in animal studies, administration of amiodarone to rabbits, rats, and mice during organogenesis resulted in embryo- fetal toxicity at dos